---
title: "Birla Pacific Medspa Ltd (533469) — Share Price, Financials & Analysis"
symbol: "533469"
company: "Birla Pacific Medspa Ltd"
canonical: "https://tapetide.com/stocks/533469"
isin: "INE341L01017"
bse_code: "533469"
generated_at: "2026-10-13T10:59:37.359Z"
---

# Birla Pacific Medspa Ltd (533469)

Canonical page: https://tapetide.com/stocks/533469

## Company

- **BSE Code:** 533469
- **ISIN:** INE341L01017
- **Stock Type:** EQUITY
- **Listed Since:** 2011-07-07
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** birlapacificmedspa.com

## About

Birla Pacific Medspa Limited, incorporated in India, Listed on the Bombay Stock exchange Limited, the company is engaged in the business of medical, health care treatments.

## Latest Price

## Key Insights

### Strengths

- Company is almost debt free.
- Stock is trading at 0.03 times its book value

### Weaknesses

- Company has a low return on equity of -2.28% over last 3 years.
- Working capital days have increased from 4,290 days to 10,522 days

## Growth Rates

| Metric | 1Y | 3Y |
| --- | --- | --- |
| net income growth | 179% | 40% |
| revenue growth | -70% | -14% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2013 | Jun 2013 | Sep 2013 | Dec 2013 |
| --- | --- | --- | --- | --- |
| Sales | 0.08 | 0.1 | 0.19 | 0.28 |
| Expenses | 1.14 | 0.19 | 0.43 | 0.61 |
| Operating Profit | -1.06 | -0.09 | -0.24 | -0.33 |
| OPM % | -1325 | -90 | -126.32 | -117.86 |
| Other Income | -8.14 | 0.61 | 0.72 | 0.72 |
| Interest | 0 | 0 | 0 | 0 |
| Depreciation | 0.16 | 0.14 | 0.14 | 0.14 |
| Profit before tax | -9.36 | 0.38 | 0.34 | 0.25 |
| Tax % | 0 | 0 | 0 | 0 |
| Net Profit | -9.36 | 0.38 | 0.34 | 0.25 |
| EPS in Rs | -0.83 | 0.03 | 0.03 | 0.02 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2009 15m | Mar 2010 6m | Mar 2011 | Mar 2012 | Mar 2013 | TTM |
| --- | --- | --- | --- | --- | --- | --- |
| Sales | 1.7 | 1.53 | 2.13 | 3.32 | 0.98 | 0.65 |
| Expenses | 6.27 | 2.64 | 5.52 | 5.17 | 2.54 | 2.37 |
| Operating Profit | -4.57 | -1.11 | -3.39 | -1.85 | -1.56 | -1.72 |
| OPM % | -268.82 | -72.55 | -159.15 | -55.72 | -159.18 | -264.62 |
| Other Income | 0 | 0 | 0.1 | 1.29 | -6.22 | -6.09 |
| Interest | 0.01 | 0.01 | 0.02 | 0.03 | 0.01 | 0 |
| Depreciation | 0 | 0.5 | 1.12 | 0.99 | 0.8 | 0.58 |
| Profit before tax | -4.58 | -1.62 | -4.43 | -1.58 | -8.59 | -8.39 |
| Tax % | 0 | 0 | 0 | 0 | 0 | — |
| Net Profit | -4.58 | -1.62 | -4.43 | -1.57 | -8.6 | -8.39 |
| EPS in Rs | — | — | — | -0.14 | -0.77 | -0.75 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 |
| --- | --- | --- | --- | --- | --- |
| Equity Capital | 5.55 | 10.47 | 46.97 | 112.14 | 112.14 |
| Reserves | -4.58 | 8.64 | -3.4 | -5.68 | -14.27 |
| Borrowings | 0 | 0 | 0.1 | 0.16 | 0.6 |
| Other Liabilities | 8.02 | 1.64 | 1.42 | 0.78 | 0.79 |
| Total Liabilities | 8.99 | 20.75 | 45.09 | 107.4 | 99.26 |
| Fixed Assets | 5.27 | 5.16 | 5.32 | 4.86 | 3.19 |
| CWIP | 0.08 | 0.37 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0.25 | 2.41 | 0.51 |
| Other Assets | 3.64 | 15.22 | 39.52 | 100.13 | 95.56 |
| Total Assets | 8.99 | 20.75 | 45.09 | 107.4 | 99.26 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 |
| --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | -4.51 | -11.44 | -27.7 | 14.19 | -4.56 |
| Cash from Investing Activity | -6.2 | -0.66 | -1.18 | -76.88 | 2.14 |
| Cash from Financing Activity | 11.96 | 11.09 | 28.97 | 64.5 | 0.43 |
| Net Cash Flow | 1.25 | -1.01 | 0.09 | 1.81 | -1.99 |
| Free Cash Flow | -10.71 | -12.1 | -28.64 | -40.02 | -4.61 |
| CFO/OP | 99 | 1031 | 817 | -772 | 270 |

### Ratios

| Item | Sep 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 |
| --- | --- | --- | --- | --- | --- |
| Debtor Days | 19.32 | 21.47 | 12 | 2.2 | 7.45 |
| Inventory Days | 94.63 | 158.7 | 232.27 | 176.21 | 334.58 |
| Days Payable | 0 | 2428.04 | 2040.68 | 742.59 | 2068.33 |
| Cash Conversion Cycle | 113.95 | -2247.88 | -1796.41 | -564.18 | -1726.3 |
| Working Capital Days | -1208.79 | 2252.03 | -75.4 | 2423.07 | 10521.68 |
| ROCE % | — | — | -14.02 | -2.06 | 1.23 |

## Shareholding Pattern

### annual

| Category | Mar 2024 | Mar 2025 | Dec 2025 |
| --- | --- | --- | --- |
| Promoters | 74.88% | 72.7% | 72.66% |
| FIIs | 9.87% | 12.92% | 11.34% |
| DIIs | 11.14% | 11.47% | 13.26% |
| Public | 4.1% | 2.89% | 2.75% |
| No. of Shareholders | 135116 | 180597 | 177539 |

### Quarterly

| Category | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 76.5% | 76.5% | 76.5% | 74.88% | 74.87% | 74.87% | 72.71% | 72.7% | 72.67% | 72.67% | 72.66% |
| FIIs | 4.18% | 4.18% | 6.74% | 9.87% | 11.58% | 12.37% | 13.34% | 12.92% | 13.07% | 12.83% | 11.34% |
| DIIs | 4.65% | 4.56% | 9.78% | 11.14% | 9.94% | 9.91% | 11.05% | 11.47% | 11.5% | 11.91% | 13.26% |
| Public | 14.67% | 14.76% | 6.97% | 4.1% | 3.61% | 2.86% | 2.89% | 2.89% | 2.75% | 2.57% | 2.75% |
| No. of Shareholders | 131918 | 134731 | 127449 | 135116 | 153450 | 163854 | 171281 | 180597 | 179549 | 170347 | 177539 |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 2026-02-27 | [Clarification Submitted By Mankind Pharma Limited](https://www.bseindia.com/xml-data/corpfiling/AttachHis/33fa5709-5c00-4f37-a301-eea81b8d550d.pdf) |
| 2026-02-26 | [Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015](https://www.bseindia.com/xml-data/corpfiling/AttachHis/56c33a97-48c8-45f6-99de-14c0e3b21694.pdf) |
| 2026-02-24 | [Announcement under Regulation 30 (LODR)-Credit Rating](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d8d650ed-26c3-4f25-82f2-752dbc498b88.pdf) |
| 2026-02-18 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/xml-data/corpfiling/AttachHis/db96c8ea-d813-403b-a21a-2eb572b9cc55.pdf) |
| 2026-02-16 | [Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1c36a6e6-ac15-438d-8f03-0c94d6da906e.pdf) |
| 2026-02-09 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/xml-data/corpfiling/AttachHis/49858517-2821-4378-ab5b-bee857346a00.pdf) |
| 2026-02-09 | [Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9521c78f-7cfe-4c1e-b465-a3634cc30df5.pdf) |
| 2026-02-04 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/xml-data/corpfiling/AttachHis/666b1ce3-8aec-4074-9f11-43e3e624c210.pdf) |
| 2026-02-04 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b8340728-4dd5-4607-8a83-a0620e282eb8.pdf) |
| 2017-05-09 | [Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=07FEB8F9_A9A7_4D26_AA9D_37E823932884_110242.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| 2025 | [Financial Year 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f4249a79-2986-44b0-b7d4-a24ec3409ba9.pdf) |
| 2024 | [Financial Year 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b6f4cbc2-fac4-4ed6-9738-115aa45b2eb7.pdf) |
| 2023 | [Financial Year 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0b98b421-ddb7-4c51-93e8-c2e6c35e6db2.pdf) |
| Mar 2013 | [Annual Report 2013](https://www.bseindia.com/bseplus/AnnualReport/533469/5334690313.pdf) |
| Mar 2012 | [Annual Report 2012](https://www.bseindia.com/bseplus/AnnualReport/533469/5334690312.PDF) |
| Mar 2011 | [Annual Report 2011](https://www.bseindia.com/bseplus/AnnualReport/533469/5334690311.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Feb 2026 | [Concall - Feb 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/49858517-2821-4378-ab5b-bee857346a00.pdf) |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/09896907-dd89-468c-869d-25ae30374415.pdf) |
| Aug 2025 | [Concall - Aug 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1c81dfdb-7723-4f42-a476-4753e4c7086b.pdf) |
| May 2025 | [Concall - May 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b6d2d808-2fb6-4350-a73a-0df90d043dfa.pdf) |
| Jan 2025 | [Concall - Jan 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/09cab4ef-bf88-40b1-be1e-cabdff929690.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1fde1a79-c646-4353-b99b-69b0f12d9383.pdf) |
| Sep 2024 | [Concall - Sep 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/87dce799-cad1-4805-8128-4d819376836c.pdf) |
| Aug 2024 | [Concall - Aug 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6a384929-2141-47eb-9bca-03ecbabb60e0.pdf) |
| Aug 2024 | [Concall - Aug 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/8d30e4d4-4e89-464c-bc32-91c670ef6391.pdf) |
| Aug 2024 | [Concall - Aug 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/48686b39-01f2-4ab2-a614-0378c6d56f6c.pdf) |

### Credit Rating Reports

| Date | Document |
| --- | --- |
| 2026-02-24 | Credit rating update — ICRA |
| 2026-01-16 | Credit rating update — ICRA |
| 2025-11-13 | Credit rating update — ICRA |
| 2025-10-29 | Credit rating update — CRISIL |
| 2025-03-25 | Credit rating update — CARE Ratings |
| 2025-02-25 | Credit rating update — ICRA |
| 2024-11-05 | Credit rating update — CRISIL |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-10-13T10:59:37.359Z.